Birth control pill has lasting protective effects against endometrial cancer
the ONA take:
A new study from researchers at the University of Oxford in the United Kingdom reports that oral contraceptives protect against endometrial cancer, and the protective benefit lasts for many years after women stop taking the pills.
Previous studies linked the use of the birth control pill with reduced incidence of endometrial cancer, but whether this continued after the use is discontinued was unknown.
In this study, the researchers used a dataset that included 27,276 women with endometrial cancer and 115,743 women without the disease from 36 epidemiological studies.
They calculated that the risk of endometrial cancer was reduced by approximately 25% for every 5 years of use. Furthermore, the reduced risk persisted for more than 30 years after birth control pills were discontinued.
The decrease in the amount of estrogen birth control pills also did not diminish the protective effects of oral contraceptive use.
An estimated 400,000 cases of endometrial cancer were prevented in developed countries due to the use of birth control pills between 1965 and 2014, with approximately 200,000 cases prevented after 2005.
Oral contraceptives protect against endometrial cancer, and the protective benefit lasts for many years after women stop taking the pills.
- FDA Grants Approval to Bevacizumab-awwb as First Biosimilar for Anticancer Therapy
- Efficacy of Octreotide LAR, Lanreotide in Management of Carcinoid Tumors
- Multivitamin Use May Reduce Risk of Chemo-Induced Neuropathy
- Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination
- Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC
- Invisible Burdens: The Complex Needs of Caregivers of Patients With Brain Cancer
- Cannabis Reduces Response Rate to Immunotherapy for Cancer
- Perioperative Blockade of Pathways May Improve Outcomes in Breast Cancer
- Zika Virus Preferentially Targets Glioblastoma Stem Cells
- Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications
- Lorazepam Plus Haloperidol Improves Agitation in Cancer-Related Delirium
- Cost of Care Significantly Increased With Carcinoid Syndrome in NETs
- Treating Intractable Hiccups in Advanced Cancer, Palliative Care Setting
- Severe Mental Illness May Worsen Breast Cancer Survival Outcomes
- Imaging Management of Breast Density, a Controversial Risk Factor for Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|